|Day Low/High||81.61 / 82.92|
|52 Wk Low/High||73.69 / 89.09|
Research finds gifting livestock improves diets, incomes, lessens poverty
Jim discusses his thoughts on Kohl's quarter, a Raytheon downgrade, 3M, and answers a club member's question.
President Trump has been all bluster and tweets when it comes to the pharma industry and drug pricing. HHS Secretary Azar, though, seems to be serious about making changes.
Aimovig is the first treatment approved by the agency to prevent migraines by blocking the calcitonin gene-related peptide receptor.
Jim discusses Macy's quarter as a readthrough to Nordstrom, defense and North Korea, and more on the market!
Corporate America may not be giving it straight to investors. That could come back to bite them in the remaining quarters of 2018.
Jim Cramer focuses on Berkshire Hathaway, Align Technology, Seaspan, Criticare Systems, CoreSite Realty, Hi-Crush Partners and more.
Jim Cramer asks, why is there such a double-standard? Why do selloffs have instant credibility and advances are to be doubted?
Taking advantage of recent gains in Lilly to shift more allocation to WestRock and Textron.
President Trump reduced tensions in Korea, raised them in the Middle East, and mainly relieved them for investors in the drug and healthcare industries.
The markets strongly rebounded this week as a few of the major averages pushed into positive year-to-date territory.
Jim Cramer takes a look at Verizon, Chipotle, Bank of Internet, Oracle, PayPal, Raytheon, Mallinckrodt, Roku, McDonald's.
Take one part great earnings and one part tremendous skepticism, add in low inflation and you end up with this astonishing stealth rally. Jim Cramer explains it.
All three major averages closed Thursday's session in positive territory.
Jim discusses expectations for Nvidia's earnings release, oil and our initiation in Anadarko Petroleum.
Indiana-based company adds Michael-Bryant Hicks to leadership team
We initiated 2 new positions and exited another during a busy week for the portfolio.
The Israel-based drugmaker reported first-quarter numbers that surpassed analysts' expectations but Wall Street wants to see more.
This is an opportunity to add to our position in this best-in-class financial at our lowest price to date.
We will make a small sale in LLY and use the proceeds and opportunity to scoop up more PEP.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.